Category Archives: Cyclosporine

Osteoporosis Drug Could Lead to Hair Loss Treatment

A new hair related study out from the UK’s University of Manchester has been making global news as a potential cure for baldness for the past several hours. The paper is titled: Identifying novel strategies for treating human hair loss disorders: Cyclosporine A suppresses the Wnt inhibitor, SFRP1, in the dermal papilla of human scalp hair follicles and was released in in the open access journal “PLOS Biology”. The lead author is Dr. Nathan Hawkshaw, and one of the co-authors is Dr. Ralf Paus (who I have covered a number of times on this blog in the past). A summary of this latest work can be read here.

Dr. Nathan Hawkshaw
Dr. Nathan Hawkshaw

Note that despite the title of the study, the main subject matter is not Cyclosporine A (CsA), but rather, an unrelated drug called WAY-316606. I will discuss the actual findings of this research in the next section.

For regular readers of this blog, this is not a surprising development. I covered Cyclosporine and hair growth in detail in 2016. It should be noted, however, that past research has focused on Cyclosporine’s anti-inflammatory and autoimmune properties (as is the case with JAK inhibitors). However, this latest research found an alternative mechanism via which Cyclosporine A benefits hair growth.

The researchers, via gene expression analysis, discovered that CsA inhibits a protein called SFRP1, which in turn is responsible for blocking the Wnt pathway and hindering hair growth. Also note that this latest work was conducted on human hair follicles. Most past research has involved mice hair or other mammalian cell culture.

Osteoporosis Drug WAY-316606 for Hair Growth

More importantly, this latest research went one crucial step further. The researchers found that an already existing SFRP1 antagonist drug to treat osteoporosis (brittle bones) was several times more effective than CsA at growing hair in humans. This drug is called WAY-316606.

Moreover, while CsA has major potential side effects, the same is not true for WAY-316606. Note that while CsA is an immunosupresant, WAY-316606 is a non-immunosppressive, chemically unrelated agent.

According to the BBC:

Project leader Dr Nathan Hawkshaw said it could “make a real difference to people who suffer from hair loss”.

According to the more tabloidy SUN:

Dr. Hawkes said “I’m very optimistic it could work. In lab tests, the drug started promoting growth in hair follicles in just two days. We are looking at using it as a topical treatment, a gel or shampoo that could reach the follicle. Dr Hawkshaw said there are no known side-effects of the bone drug“.

Update: The University of Manchester now has an article on it.

Wnt signaling has been covered at least briefly by me in what must be several dozen blog posts by now. A number of companies are working on curing hair loss by targeting the Wnt pathway, with the most famous of these being Samumed.

Now we have one more name to add to that list.

Cyclosporine for Hair Loss Revisited

During the past several years, the single biggest breakthrough in hair loss treatments has been in the form of Janus Kinase (JAK) inhibitors curing alopecia areata (AA), alopecia totalis and alopecia universalis in most test patients. You can find numerous posts on that subject on this blog if you browse through the categories menu.

While JAK inhibitors seem to be close to a cure for a majority of patients suffering from alopecia areate (as well as from many other autoimmune related disorders such as vitiligo,  psoriasis and rheumatoid arthritis), their effect on patients with androgenetic alopecia (aka male pattern hair loss, which is by far and away the dominant variety of hair loss in humans) is unproven and controversial to put it mildly. A US based company named Aclaris Therapeutics (based on the work of Dr. Angela Christiano) has claimed that there is a good chance that specialized covalently bound topical JAK inhibitors will cure androgenetic alopecia (AGA) in many patients (oral JAK inhibitors do not work for AGA but do work for AA). The implication is that male pattern hair loss might have a significant autoimmune component to it, a conclusion that it seems is not supported by many hair loss researchers. It is also possible that topical JAK inhibitors could be helping hair growth via a totally different mechanism unrelated to the immune system.

Cyclosporine A and Hair Growth

Some time ago, I mentioned a study that showed oral cyclosporine A (also referred to as ciclosporin A or as CyA) to benefit scalp hair growth in some men with androgenetic alopecia. I thought it significant that well before JAK inhibitors came on to the scene, there was already a drug in the form of cyclosporine that targeted the immune system and that seemed to benefit scalp hair growth in some patients. However, several bloggers mentioned that topical cyclosporine experiments by some hair loss sufferers did not seem to lead to any decent results insofar as scalp hair regrowth goes. Moreover, the effect of JAK inhibitors versus that of cyclosporine is very different (more on that further below), and the past studies linking cyclosporine and hair growth are somewhat ambiguous (more on that further below). I therefore decided to relegate cyclosporine to the backburner for a future post and forgot about it until….

RiverTown Therapeutics and their Cyclosporine Product

The biggest news in the hair loss world this month has been RiverTown Therapeutics’ new website. I have generally not been too keen about this company even though I have mentioned them several times in my blog posts this year.

My two biggest reasons for being pessimistic about RiverTown are the facts that:

  1. Minoxidil by itself can give great results in terms of hair growth in some people (so their Minoxidil containing RT1640 product could just be glorified Minoxidil). And a company named Follica (US) has already tried a wounding plus Minoxidil approach that is likely superior to just Minoxidil.
  2. RiverTown has not even conducted phase 1 clinical trials for RT1640 at present per their product pipeline page, and by the time all 3 clinical trials are concluded, we could very well have a few more superior treatments on the market (Follica, Histogen, Tsuji, Shiseido and more).

Adding to my skepticism about RiverTown are small details such as its actual home page still saying “under construction” as of today, and the CEO’s Linkedin profile not even having RiverTown listed in there (I thought it was there in the past?).

Having said that, I was pleased to learn that the respected hair loss researchers Dr. Elaine Fuchs and Dr. Maria Hordinsky (the former has been mentioned on this blog many times before) are both on RiverTown’s scientific advisory board. Moreover, RiverTown’s CEO David Weinstein was previously associated with a company named GliaMed, and they had a product called GM1485 that never came to market, but that supposedly (in animals) promoted “the regeneration of all components of the skin after injury, including nerves, hair follicles, blood vessels, dermis and epidermis with minimal scarring”. Encouraging.

Hopefully the fact that last week the US House of Representative overwhelmingly supported the passage of the 21st Century Cures Act will help RiverTown and other companies in the hair loss world bring forth their products to market significantly faster, without having to move to Japan.

In any event, getting back to the subject matter of this post, the reason I mention RiverTown is because the new website clarifies that the company’s RT1640 hair loss product contains three ingredients, one of which is cyclosporine A:

  • Minoxidil (already FDA approved).
  • Cyclosporine A (already FDA approved).
  • RT175 (a proprietary chemical entity developed by one of Rivertown’s co-founders that has been tested in 600 humans).

Cyclosporine A and Hair Loss Studies from the Past

So now I had to look up all the past studies that mention Cyclosporine and hair in the same page. Below is a chronological list of the most important such studies, with my notes in blue.

  • Cyclosporine and Male-Pattern Alopecia, 1987 (US). Just 1 patient, but a very positive result with new hair growth in the temporal region of the scalp when on cyclosporine, which then went away when off the drug. An interesting quote: “Hypertrichosis has been reported to occur in 60% of kidney transplant recipients treated with cyclosporine”. Hypertrichosis means excessive body hair. If something can grow new body hair (or convert vellus body hair to terminal body hair), it is surely not out of the realm that it can also grow new scalp hair? It should be noted, however, that cyclosporin might be increasing DHT levels and that could be increasing body hair.
  • Topical Cyclosporine in Male Pattern Alopecia1990 (Israel — from the prestigious Technion University). The now deceased forum member Bryan pasted the whole study for is on HLH2 out of 8 human subjects who suffered from AGA saw significant growth when on topical cyclosporine for 4 months. One 1 of those 2 saw cosmetically evident growth. Same authors have another study from 1988 based on transplanted human hair onto mice, and they concluded that cyclosporine A may be effective in the treatment of alopecia.
  • Effects of Cyclosporin A on Hair, 1994 (Germany). A very interesting statement in “One of the most common dermatological side effects of oral CyA is dose-dependent hypertrichosis”. It seems like CyA causes new body hair to develop from vellus hair. Also, the conclusion is that oral application of CyA proved successful in treating AA as well as AGA (!). However, the topical application failed to treat either condition.
  • Hair Growth-Stimulating Effects of Cyclosporin A and FK506, Potent Immunosuppressants,  1994 (Japan). A bit confusing in that they seem to discuss body hair and scalp hair alternately. In any case, they state that “the hair growth stimulating effect of CsA is observed not only in normal but also in pathological conditions of hair growth, i.e. in patients with alopecia areata and also in some patients with male-pattern alopecia“.

Cyclosporine A Versus JAK inhibitors

While cyclosporine A and JAK inhibitors both have immunosupressive properties, their mechanism of action is different.

According to the earlier mentioned Japanese study, cyclosporine A inhibits T-cell activation by “interfering with the production of interleukin-2 (IL-2) by inhibiting IL-2 gene expression, probably through the inhibition of calcineurin, a Ca2+/calmodulin-dependent phosphatase”. A bit difficult but not impossible to understand. Cyclosporine is used for a number of inflammatory skin conditions, especially psoriasis.

JAK inhibitors are a type of medication that inhibit the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2). In the process, they interfere with the critical JAK-STAT signaling pathway. Aclaris is working on a  topical covalently binding, highly selective JAK3 inhibitor to cure AGA.

I hope the five or so scientifically highly astute commentators that we have had on this blog to date can further compare and discuss JAK inhibitors versus CsA, since my knowledge in this area is very limited.

My Hypothesis

Over the years, I have read numerous online forum posts from people stating that when they started losing their hair, they also started getting a lot of scalp itching (largely in the same areas where they were also experiencing hair loss). I have witnessed the exact same phenomenon on my own scalp and use Nizoral to tackle the problem whenever it arises.

This has led me to wonder whether people who have male pattern hair loss combined with a lot of associated itching, inflammation and dandruff also have an autoimmune component to their hair loss? Perhaps men with male pattern hair loss can be divided into two broad categories: those with an autoimmune component to their hair loss (and itchy scalps), and those without any autoimmune component (and normal scalps with no itching) ? The fact that both the immunosuppressant drugs CsA and JAK inhibitors can help some men with male pattern hair loss makes this hypothesis less far fetched than it might have originally seemed in my opinion.